Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells

Experimental Cell Research

Volumn 322, Issue 2, 2014, Pages 402-414

  Berndt, Alexander ^a   Büttner, Robert ^b   Gühne, Stefanie ^a   Gleinig, Anna ^a   Richter, Petra ^a   Chen, Yuan ^a   Franz, Marcus ^a   Liebmann, Claus ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cell cycle; EGFR signaling; EMT; OSCC; Tumour associated fibroblasts

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR AB; PROTEIN KINASE B; STAT3 PROTEIN; VIMENTIN;

ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STIMULATION; HUMAN; HUMAN CELL; MOUTH SQUAMOUS CELL CARCINOMA; MUTATION; MYOFIBROBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL CYCLE; EGFR SIGNALING; EMT; OSCC; TUMOUR ASSOCIATED FIBROBLASTS;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CULTURE MEDIA, CONDITIONED; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MOUTH NEOPLASMS; MUTATION; MYOFIBROBLASTS; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; VIMENTIN;

EID: 84896044945     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.12.024     Document Type: Article

References (59)

1. Morris L.G., Taylor B.S., Bivona T.G., Gong Y., Eng S., Brennan C.W., Kaufman A., Kastenhuber E.R., Banuchi V.E., Singh B., Heguy A., Viale A., Mellinghoff I.K., Huse J., Ganly I., Chan T.A. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc. Nat. Acad. Sci. U.S.A. 2011, 108:19024-19029.
2. Mink S.R., Vashistha S., Zhang W., Hodge A., Agus D.B., Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol. Cancer Res. 2010, 8:809-820.
3. Wang W., Li Q., Yamada T., Matsumoto K., Matsumoto I., Oda M., Watanabe G., Kayano Y., Nishioka Y., Sone S., Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 2009, 15:6630-6638.
4. Ostman A. The tumor microenvironment controls drug sensitivity. Nat. Med. 2012, 18:1332-1334.
5. Johansson A.C., Ansell A., Jerhammar F., Lindh M.B., Grenman R., Munck-Wikland E., Ostman A., Roberg K. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Mol. Cancer Res. 2012, 10:1158-1168.
6. Strell C., Rundqvist H., Ostman A. Fibroblasts-a key host cell type in tumor initiation, progression, and metastasis. Ups. J. Med. Sci. 2012, 117:187-195.
7. Matsumoto K., Horikoshi M., Rikimaru K., Enomoto S. A study of an in vitro model for invasion of oral squamous cell carcinoma. J. Oral. Pathol. Med. 1989, 18:498-501.
8. Berndt A., Hyckel P., Konneker A., Katenkamp D., Kosmehl H. Oral squamous cell carcinoma invasion is associated with a laminin-5 matrix re-organization but independent of basement membrane and hemidesmosome formation. Clues from an in vitro invasion model. Invasion Metastasis 1997, 17:251-258.
9. Costea D.E., Kulasekara K., Neppelberg E., Johannessen A.C., Vintermyr O.K. Species-specific fibroblasts required for triggering invasiveness of partially transformed oral keratinocytes. Am. J. Pathol. 2006, 168:1889-1897.
10. Chaw S.Y., Majeed A.A., Dalley A.J., Chan A., Stein S., Farah C.S. Epithelial to mesenchymal transition (EMT) biomarkers - E-cadherin, beta-catenin, APC and vimentin - in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012, 48:997-1006.
11. Gaggioli C. Collective invasion of carcinoma cells: when the fibroblasts take the lead. Cell Adh. Migr. 2008, 2:45-47.
12. Briest F., Berndt A., Clement J., Junker K., Eggeling F., Grimm S., Friedrich K. Tumor-stroma interactions in tumorigenesis: lessons from stem cell biology. Front. Biosci. 2012, 4:1871-1887. (Elite Ed).
13. Marsh T., Pietras K., McAllister S.S. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 2012.
14. Lyons A.J., Jones J. Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int. J. Oral. Maxillofac. Surg. 2007, 36:671-679.
15. Kellermann M.G., Sobral L.M., da Silva S.D., Zecchin K.G., Graner E., Lopes M.A., Kowalski L.P., Coletta R.D. Mutual paracrine effects of oral squamous cell carcinoma cells and normal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation. Oral Oncol. 2008, 44:509-517.
16. Thode C., Jorgensen T.G., Dabelsteen E., Mackenzie I., Dabelsteen S. Significance of myofibroblasts in oral squamous cell carcinoma. J. Oral. Pathol. Med. 2011, 40:201-207.
17. Marsh D., Suchak K., Moutasim K.A., Vallath S., Hopper C., Jerjes W., Upile T., Kalavrezos N., Violette S.M., Weinreb P.H., Chester K.A., Chana J.S., Marshall J.F., Hart I.R., Hackshaw A.K., Piper K., Thomas G.J. Stromal features are predictive of disease mortality in oral cancer patients. J. Pathol. 2011, 223:470-481.
18. de-Assis E.M., Pimenta L.G., Costa-e-Silva E., Souza P.E., Horta M.C. Stromal myofibroblasts in oral leukoplakia and oral squamous cell carcinoma. Med. Oral Patol. Oral Cir. Bucal 2012, 17:e733-e738.
19. Lewis M.P., Lygoe K.A., Nystrom M.L., Anderson W.P., Speight P.M., Marshall J.F., Thomas G.J. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer 2004, 90:822-832.
20. Sobral L.M., Bufalino A., Lopes M.A., Graner E., Salo T., Coletta R.D. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol. 2011, 47:840-846.
21. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73.
22. Schulte J., Weidig M., Balzer P., Richter P., Franz M., Junker K., Gajda M., Friedrich K., Wunderlich H., Ostman A., Petersen I., Berndt A. Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells. Histochem. Cell Biol. 2012, 138:847-860.
23. Micalizzi D.S., Farabaugh S.M., Ford H.L. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia 2010, 15:117-134.
24. Lim J., Thiery J.P. Epithelial-mesenchymal transitions: insights from development. Development 2012, 139:3471-3486.
25. Smith A., Teknos T.N., Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2012.
26. Nijkamp M.M., Span P.N., Hoogsteen I.J., van der Kogel A.J., Kaanders J.H., Bussink J. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother. Oncol. 2011, 99:344-348.
27. Nguyen P.T., Kudo Y., Yoshida M., Kamata N., Ogawa I., Takata T. N-cadherin expression is involved in malignant behavior of head and neck cancer in relation to epithelial-mesenchymal transition. Histol. Histopathol. 2011, 26:147-156.
28. Vered M., Dayan D., Yahalom R., Dobriyan A., Barshack I., Bello I.O., Kantola S., Salo T. Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int. J. Cancer 2010, 127:1356-1362.
29. Onoue T., Uchida D., Begum N.M., Tomizuka Y., Yoshida H., Sato M. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int. J. Oncol. 2006, 29:1133-1138.
30. Dudas J., Bitsche M., Schartinger V., Falkeis C., Sprinzl G.M., Riechelmann H. Fibroblasts produce brain-derived neurotrophic factor and induce mesenchymal transition of oral tumor cells. Oral Oncol. 2011, 47:98-103.
31. Yu C., Liu Y., Huang D., Dai Y., Cai G., Sun J., Xu T., Tian Y., Zhang X. TGF-beta1 mediates epithelial to mesenchymal transition via the TGF-beta/Smad pathway in squamous cell carcinoma of the head and neck. Oncol. Rep. 2011, 25:1581-1587.
32. Richter P., Umbreit C., Franz M., Berndt A., Grimm S., Uecker A., Bohmer F.D., Kosmehl H. EGF/TGFbeta1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332. J. Oral. Pathol. Med. 2011, 40:46-54.
33. Al Moustafa A.E., Achkhar A., Yasmeen A. EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front. Biosci. 2012, 4:671-684. (Schol Ed).
34. Zuo J.H., Zhu W., Li M.Y., Li X.H., Yi H., Zeng G.Q., Wan X.X., He Q.Y., Li J.H., Qu J.Q., Chen Y., Xiao Z.Q. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J. Cell. Biochem. 2011, 112:2508-2517.
35. Maseki S., Ijichi K., Tanaka H., Fujii M., Hasegawa Y., Ogawa T., Murakami S., Kondo E., Nakanishi H. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br. J. Cancer 2012, 106:1196-1204.
36. Agell L., Hernandez S., Salido M., de Muga S., Juanpere N., Arumi-Uria M., Menendez S., Lorenzo M., Lorente J.A., Serrano S., Lloreta J. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod. Pathol. 2011, 24:443-452.
37. Wong C.W., Fan Y.S., Chan T.L., Chan A.S., Ho L.C., Ma T.K., Yuen S.T., Leung S.Y. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J. Clin. Pathol. 2005, 58:640-644.
38. Do H., Krypuy M., Mitchell P.L., Fox S.B., Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8:142.
39. Hickinson D.M., Marshall G.B., Beran G.J., Varella-Garcia M., Mills E.A., South M.C., Cassidy A.M., Acheson K.L., McWalter G., McCormack R.M., Bunn P.A., French T., Graham A., Holloway B.R., Hirsch F.R., Speake G. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin. Transl. Sci. 2009, 2:183-192.
40. Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 2011, 68:3033-3046.
41. Chang C.C., Hsu W.H., Wang C.C., Chou C.H., Kuo M.Y., Lin B.R., Chen S.T., Tai S.K., Kuo M.L., Yang M.H. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 2013, 73:4147-4157.
42. Lin X.D., Chen S.Q., Qi Y.L., Zhu J.W., Tang Y., Lin J.Y. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J. Surg. Oncol. 2012, 106:94-100.
43. Kornfeld J.W., Meder S., Wohlberg M., Friedrich R.E., Rau T., Riethdorf L., Loning T., Pantel K., Riethdorf S. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br. J. Cancer 2011, 104:138-145.
44. Fan H.X., Li H.X., Chen D., Gao Z.X., Zheng J.H. Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications. J. Exp. Clin. Cancer Res. 2012, 31:90.
45. Kulasekara K.K., Lukandu O.M., Neppelberg E., Vintermyr O.K., Johannessen A.C., Costea D.E. Cancer progression is associated with increased expression of basement membrane proteins in three-dimensional in vitro models of human oral cancer. Arch. Oral Biol. 2009, 54:924-931.
46. Hickinson D.M., Klinowska T., Speake G., Vincent J., Trigwell C., Anderton J., Beck S., Marshall G., Davenport S., Callis R., Mills E., Grosios K., Smith P., Barlaam B., Wilkinson R.W., Ogilvie D. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 2010, 16:1159-1169.
47. Brave S.R., Odedra R., James N.H., Smith N.R., Marshall G.B., Acheson K.L., Baker D., Howard Z., Jackson L., Ratcliffe K., Wainwright A., Lovick S.C., Hickinson D.M., Wilkinson R.W., Barry S.T., Speake G., Ryan A.J. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int. J. Oncol. 2011, 39:271-278.
48. Dalley A.J., AbdulMajeed A.A., Upton Z., Farah C.S. Organotypic culture of normal, dysplastic and squamous cell carcinoma-derived oral cell lines reveals loss of spatial regulation of CD44 and p75 NTR in malignancy. J. Oral. Pathol. Med. 2012, 42:37-46.
49. Schleier P., Berndt A., Dahse R., Zenk W., Hyckel P., Kosmehl H. [Experimental 5-aminolevulinic acid-induced photodynamic therapy (ALA-PDT) of oral carcinomas. Procedures in treatment of solid tumors and elucidation of cell death]. Mund Kiefer Gesichtschir. 2001, 5:98-104.
50. Weisheit S., Schafer C., Mertens C., Berndt A., Liebmann C. PKCepsilon acts as negative allosteric modulator of EGF receptor signalling. Cell Signal. 2011, 23:436-448.
51. Claperon A., Mergey M., Aoudjehane L., Ho-Bouldoires T.H., Wendum D., Prignon A., Merabtene F., Firrincieli D., Desbois-Mouthon C., Scatton O., Conti F., Housset C., Fouassier L. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 2013.
52. Choi J.H., Bae S.S., Park J.B., Ha S.H., Song H., Kim J.H., Cocco L., Ryu S.H., Suh P.G. Cbl competitively inhibits epidermal growth factor-induced activation of phospholipase C-gamma1. Mol. Cells 2003, 15(2):245-255.
53. Saito T., Okada S., Ohshima K., Yamada E., Sato M., Uehara Y., Shimizu H., Pessin J.E., Mori M. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology 2004, 145:4232-4243.
54. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol. Ther. 2009, 122:1-8.
55. Giannoni E., Bianchini F., Masieri L., Serni S., Torre E., Calorini L., Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
56. Hawinkels L.J., Paauwe M., Verspaget H.W., Wiercinska E., van der Zon J.M., van der Ploeg K., Koelink P.J., Lindeman J.H., Mesker W., Ten Dijke P., Sier C.F. Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene 2012.
57. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003, 17:7-30.
58. Klein T., Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2010, 41:271-290.
59. Perlson E., Michaelevski I., Kowalsman N., Ben-Yaakov K., Shaked M., Seger R., Eisenstein M., Fainzilber M. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J. Mol. Biol. 2006, 364:938-944.